Top 3 Health Care Stocks You'll Regret Missing This Month

The healthcare sector has been a beacon of resilience and growth in recent years, and the current month is no exception. As investors seek to capitalize on the sector's potential, we have identified three healthcare stocks that stand out in terms of investment potential. These stocks have received Strong Buy ratings from analysts, with price targets suggesting over 15% upside potential in the next 12 months. They also carry Outperform Smart Scores, indicating a high likelihood of beating the market.



1. UnitedHealth (UNH) - This healthcare company offers a wide range of health insurance services, making it a resilient and low-correlation option with global macro conditions. The stock has an average price target of $624.63, which implies a 23% upside potential. UNH also has a Smart Score of eight, indicating a high likelihood of beating the market. Top-rated analyst John Ransom from Raymond James reiterated a Buy rating on the stock last week, further boosting its appeal.
2. Thermo Fisher (TMO) - This company provides scientific instruments, reagents, consumables, and software services, which are essential for life sciences, pharmaceutical, and industrial applications. TMO's average price target of $656.89 implies a 26.6% upside potential from current levels. The stock carries a Smart Score of nine, indicating a strong likelihood of outperforming the market. TMO is expected to benefit from the gradual recovery of demand for its products and services in the life sciences tools and services industry.
3. Abbott Laboratories (ABT) - Known for developing medical devices, diagnostics, and nutritional products, ABT is well-positioned to capitalize on advancements in technology and new treatments for chronic conditions. The stock's average price target implies an upside potential of 18.5%. ABT has a Smart Score of eight, indicating a high likelihood of beating the market. The company's immunology drugs, Skyrizi and Rinvoq, are expected to generate at least $15 billion in combined annual sales by 2025, with a compound annual growth rate of at least 52%. Additionally, ABT is expected to close its Cerevel Therapeutics acquisition by mid-year, which could provide additional growth opportunities.



These three healthcare stocks offer compelling investment opportunities, given their strong fundamentals, growth prospects, and analyst ratings. However, it is essential to conduct thorough due diligence and consider the specific risks and challenges associated with each stock. By staying informed and making well-researched investment decisions, investors can capitalize on the growth potential of the healthcare sector and build a strong portfolio.

In conclusion, the healthcare sector remains an attractive investment option, with several stocks offering significant upside potential. By focusing on companies like UnitedHealth, Thermo Fisher, and Abbott Laboratories, investors can position themselves to benefit from the sector's growth and resilience. As always, it is crucial to maintain a diversified portfolio and stay updated with the latest developments in the healthcare sector to make informed investment decisions.